This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
EPS at Rs 32.19
Income declines marginally
Subscribe To Our Newsletter & Stay Updated
